TY - JOUR
T1 - How i treat relapsed and/or refractory multiple myeloma
AU - Lee, Hans C.
AU - Cerchione, Claudio
N1 - Funding Information:
H.C.L. would like to acknowledge support from the Baer Family
Funding Information:
H.C.L. would like to acknowledge support from the Baer Family Fund and the Goff-Street Foundation.
Publisher Copyright:
© 2020, Page Press Publications. All rights reserved.
PY - 2020
Y1 - 2020
N2 - The expanding therapeutic landscape of relapsed and/or refractory multiple myeloma (RRMM) has contributed to significant improvements in patient outcomes. These have included combinations of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), histone deacetylase inhibitors, and/or alkylating agents. More recently, the approval of the first-in-class nuclear export inhibitor selinexor and the first-in-class B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) belantamab mafodotin has helped address the current unmet need in patients refractory to PI, IMiD, and anti-CD38 mAb directed therapy, otherwise known as triple class refractory myeloma. With the growing number of treatment options in the RRMM therapeutic landscape, the choice and sequencing of drugs and combinations has become increasingly complex. In this review we discuss our approach and considerations in the treatment of both early and late RRRM based on best available data and our clinical experience.
AB - The expanding therapeutic landscape of relapsed and/or refractory multiple myeloma (RRMM) has contributed to significant improvements in patient outcomes. These have included combinations of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), histone deacetylase inhibitors, and/or alkylating agents. More recently, the approval of the first-in-class nuclear export inhibitor selinexor and the first-in-class B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) belantamab mafodotin has helped address the current unmet need in patients refractory to PI, IMiD, and anti-CD38 mAb directed therapy, otherwise known as triple class refractory myeloma. With the growing number of treatment options in the RRMM therapeutic landscape, the choice and sequencing of drugs and combinations has become increasingly complex. In this review we discuss our approach and considerations in the treatment of both early and late RRRM based on best available data and our clinical experience.
UR - http://www.scopus.com/inward/record.url?scp=85091656507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091656507&partnerID=8YFLogxK
U2 - 10.4081/hr.2020.8955
DO - 10.4081/hr.2020.8955
M3 - Article
C2 - 33042504
AN - SCOPUS:85091656507
SN - 2038-8322
VL - 12
SP - 11
EP - 12
JO - Hematology Reports
JF - Hematology Reports
IS - S1
ER -